Global Cord Blood Corporation (CO)
| Market Cap | 634.06M |
| Revenue (ttm) | 176.51M |
| Net Income (ttm) | 77.36M |
| Shares Out | 121.69M |
| EPS (ttm) | 0.65 |
| PE Ratio | 8.14 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $5.26 |
| Previous Close | $5.19 |
| Change ($) | 0.07 |
| Change (%) | 1.35% |
| Day's Open | 5.19 |
| Day's Range | 5.10 - 5.27 |
| Day's Volume | 62,936 |
| 52-Week Range | 3.24 - 6.31 |
Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY t...
HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processi...
HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...
The company received an acquisition offer.
HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...
HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processi...
HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processin...
CO is a market leader with more net cash than the market cap and our price target is $6.00 [45% upside]. 1HFY2021 results saw total subscriber numbers grow by 10%, despite tough operating conditions.
Global Cord Blood Corporation (CO) CEO Ting Zheng on Q2 2021 Results - Earnings Call Transcript
HONG KONG, Nov. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...
Investors who are screening for value opportunities may want to consider the following stocks since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-...
HONG KONG, Sept. 17, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem ce...
Global Cord Blood Corporation: June Quarter YoY EPS Of 22%, Subscriber Growth, And Total 183% Net Cash
Global Cord Blood Corporation (CO) CEO Tina Zheng on Q1 2021 Results - Earnings Call Transcript
HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...
Global Cord Blood: 20% EPS 5-Year CAGR, 17% FCF Yield - Investing In A Business For Free
HONG KONG, July 29, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cel...
Global Cord Blood Corporation (CO) CEO Tina Zheng on Q4 2020 Results - Earnings Call Transcript
As investors continue grappling with coronavirus fears, three medical companies with high financial strength and trading below Peter Lynch’s valuation line of 15 times earnings are Bio-Rad Industries Inc.
Shares of Global Cord Blood Corp. CO, -0.61% were up 0.2% in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVI...
Global Cord Blood Corporation (CO) CEO Tina Zheng on Q2 2020 Results - Earnings Call Transcript
Global Cord Blood Corporation (CO) Management on Q1 2020 Results - Earnings Call Transcript
Global Cord Blood Corporation (CO) Management on Q4 2019 Results - Earnings Call Transcript
Cordlife is proposing to merge with Global Cord Blood in what effectively is a reverse merger and a way to list Global Cord Blood on the Singaporean stock exchange.
About CO
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as C... [Read more...]
| Industry Diagnostics & Research | |
| Stock Exchange NYSE | Ticker Symbol CO |
Financial Performance
In 2019, CO's revenue was 1.22 billion, an increase of 23.79% compared to the previous year's 986.75 million. Earnings were 470.72 million, an increase of 61.69%.